Maximally titrated irbesartan, sparsentan slowed kidney decline in patients with IgAN
Click Here to Manage Email Alerts
Key takeaways:
- Patients treated with maximally titrated irbesartan had slower decline in kidney function.
- Patients treated with sparsentan also had slower kidney function decline.
LONG BEACH, Calif. — Maximally titrated irbesartan and sparsentan each slowed kidney function decline compared with real-world and clinical trial standards of care, according to data presented here.
Wu Gong, MSC, of Travere Therapeutics, presented research at the National Kidney Foundation Spring Clinical Meetings, which evaluated two study arms of the PROTECT clinical trial. The study used matching-adjusted indirect comparisons of eGFR slopes during 2 years with the U.K. National Registry of Rare Kidney Diseases IgA nephropathy (IgAN). The analysis also included real-world data from U.K. Registry patients with IgAN and a comparable clinical trial population from the NefIgArd trial.
By comparing outcomes with real-world data from U.K. National Registry patients with IgAN and a comparable clinical trial population, the researchers aimed to “evaluate the efficacy of sparsentan and [maximally titrated irbesartan] and in preserving kidney function in a broader context,” according to a press release.
Researchers used unanchored matching-adjusted indirect comparisons to match baseline patient characteristics between the PROTECT trial arms and the comparator cohort.
Results showed patients treated with either maximally titrated irbesartan or sparsentan in the PROTECT study had slower decline in kidney function compared with standard of care in both the U.K. Registry and NefIgArd cohorts. Each therapy was associated with better outcomes in slowing the progression of kidney function decline in patients with IgAN.
“The findings underscore the importance of considering 2-year eGFR slope differences between clinical trials in IgAN within the broader context of current clinical practice,” according to the release. “It also opens avenues for further research and advancements in the management of IgA nephropathy.”
Collapse
Gong W, et al. Paper 446. Presented at: NKF Spring Clinical Meetings; May 14-18, 2024; Long Beach, Calif.
Read more about
Click Here to Manage Email Alerts